Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
ANO2	rs61908406	G	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Variant was associated with an decreased likelihood of the patient entering remission, as defined by a score of 10 or more on the Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	29407288	1449168258
ANO2	rs61908408	A	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Variant was associated with an decreased likelihood of the patient entering remission, as defined by a score of 10 or more on the Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	29407288	1449168271
ANO2	rs78615940	A	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Variant was associated with an decreased likelihood of the patient entering remission, as defined by a score of 10 or more on the Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	29407288	1449168301
ANO2	rs17724464	G	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Variant was associated with an decreased likelihood of the patient entering remission, as defined by a score of 10 or more on the Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	29407288	1449168199
ANO2	rs17786394	T	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Variant was associated with an decreased likelihood of the patient entering remission, as defined by a score of 10 or more on the Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	29407288	1449168211
ANO2	rs17786412	G	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Variant was associated with an decreased likelihood of the patient entering remission, as defined by a score of 10 or more on the Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	29407288	1449168223
ANO2	rs61908402	T	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Variant was associated with an decreased likelihood of the patient entering remission, as defined by a score of 10 or more on the Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	29407288	1449168233
ANO2	rs61908403	G	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Variant was associated with an decreased likelihood of the patient entering remission, as defined by a score of 10 or more on the Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	29407288	1449168240
ANO2	rs61908410	T	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Variant was associated with an decreased likelihood of the patient entering remission, as defined by a score of 10 or more on the Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	29407288	1449168283
ANO2	rs78482393	G	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Variant was associated with an decreased likelihood of the patient entering remission, as defined by a score of 10 or more on the Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	29407288	1449168295
ANO2	rs61908407	A	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Variant was associated with an decreased likelihood of the patient entering remission, as defined by a score of 10 or more on the Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	29407288	1449168264
ANO2	rs17724452	C	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Variant was associated with an decreased likelihood of the patient entering remission, as defined by a score of 10 or more on the Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	29407288	1449168191
ANO2	rs17786400	A	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Variant was associated with an decreased likelihood of the patient entering remission, as defined by a score of 10 or more on the Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	29407288	1449168217
ANO2	rs61908404	C	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Variant was associated with an decreased likelihood of the patient entering remission, as defined by a score of 10 or more on the Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	29407288	1449168246
ANO2	rs61908405	C	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Variant was associated with an decreased likelihood of the patient entering remission, as defined by a score of 10 or more on the Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	29407288	1449168252
ANO2	rs17724494	C	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Variant was associated with an decreased likelihood of the patient entering remission, as defined by a score of 10 or more on the Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	29407288	1449168205
ANO2	rs61908411	C	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Variant was associated with an decreased likelihood of the patient entering remission, as defined by a score of 10 or more on the Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	29407288	1449168289
ANO2	rs61908409	C	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Variant was associated with an decreased likelihood of the patient entering remission, as defined by a score of 10 or more on the Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	29407288	1449168277